Topic is suspended
 
Status Suspended
Process TAG
ID number 3856

Timeline

Key events during the development of the guidance:

Date Update
30 March 2021 For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
30 March 2021 Suspended. Topic is suspended

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance